Here are the 10-K annual reports from Galectin Therapeutics Inc. (GALT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow GALT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GALT filings page.
Galectin Therapeutics Inc. files its annual report describing progress and setbacks in developing belapectin, a galectin-3 inhibitor for MASH cirrhosis and cancer. The NAVIGATE Phase 2b/3 trial reduced varices in key subgroups but missed its composite primary endpoint, leaving future Phase 3 plans uncertain. The company reported an accumulated deficit of $431 million, research and development spending of $14.3 million in 2025, and year-end unrestricted cash of $17.7 million plus a $10 million credit line from its chairman, which together are expected to fund operations only through April 2027. Galectin remains pre-revenue, depends heavily on a single financier, and disclosed a material weakness in internal control over financial reporting, while continuing to emphasize belapectin’s safety profile and biomarker improvements in advanced MASH cirrhosis.